FDA Approves New Once-Monthly Schizophrenia Injection
The newly approved treatment allows patients to avoid the three-hour observation period typically required after injections.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Do you trust long-acting injectable treatments more than traditional daily medications for managing brain disorders?
The FDA approved Weltruza, a new once-monthly schizophrenia injection, on October 9, 2026. This treatment uses advanced delivery technology to maintain stable blood levels of olanzapine for patients who struggle with daily oral medication adherence.
Why it matters
Daily oral medication for schizophrenia is frequently interrupted by missed doses, which can trigger symptom relapse. By providing a stable, month-long treatment window, this injection aims to improve medication consistency and health stability for individuals living with the condition.
The FDA approval follows the development of a drug delivery system that maintains stable blood concentrations for 4 weeks. It is still unknown how this specific formulation will compare to other existing long-acting injectables in long-term patient outcomes.
The players
FDA
The U.S. federal agency responsible for protecting public health by regulating pharmaceuticals and medical devices.
Medisorb
A pharmaceutical technology company that developed the Steaditech delivery system for medication.
Ruijie Pharmaceutical
A global pharmaceutical firm that manufactures and distributes neurological treatments.
The details
Weltruza delivers olanzapine via Medisorb's Steaditech technology, which encapsulates the medication in a biodegradable polymer. This structure degrades gradually in the body, releasing the drug steadily over time. Unlike some older versions of long-acting antipsychotics, this specific formulation removes the previous clinical requirement for patients to remain under observation for three hours following administration.
Timeline
October 9, 2026: The FDA approved Weltruza for the treatment of schizophrenia.
April 2025: Ruijie Pharmaceutical launched its schizophrenia injection, Erzoo Pro, in the U.S.
August 2025: The FDA approved a subcutaneous injection for at-home use of Leqembi.
Health Landscape
The approval of Weltruza follows the FDA's 2025 authorization of the Leqembi at-home subcutaneous injection. This shift highlights a growing focus in neurology on developing long-acting delivery systems that simplify medication administration for complex brain disorders.
If you or a family member struggle with managing daily medication schedules, this development is worth discussing with your doctor as a potential alternative. Ask your care team about how long-acting injectables might fit into a treatment plan to improve consistency and reduce the risk of symptom relapse.
The takeaway
Long-acting injectables are transforming how patients manage chronic brain conditions by replacing daily routines with sustained, stable care. Talk to your healthcare provider about whether a monthly administration schedule could offer better support for your mental health goals.
Further reading
For more information on the latest neuro-treatment developments, visit our Alzheimer’s section.
Live Poll
Do you trust long-acting injectable treatments more than traditional daily medications for managing brain disorders?
